Citations (22)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (1)
Douglas N Fish. (2006) Meropenem in the treatment of complicated skin and soft tissue infections. Therapeutics and Clinical Risk Management 2:4, pages 401-415.
Read now
Read now
Articles from other publishers (21)
Robert K Flamm, Helio S Sader, Mariana Castanheira & Ronald N Jones. (2017) The application of in vitro surveillance data for antibacterial dose selection. Current Opinion in Pharmacology 36, pages 130-138.
Crossref
Crossref
Matthew J. Labreche & Christopher R. Frei. (2012) Declining susceptibilities of gram-negative bacteria to the fluoroquinolones: Effects on pharmacokinetics, pharmacodynamics, and clinical outcomes. American Journal of Health-System Pharmacy 69:21, pages 1863-1870.
Crossref
Crossref
Mohebbi Nobandegani Zinat, Najafi Doulatabad Shahla, Rambod Masoumeh & Afraseyabi Ardeshir. (2011) Surgical site infection incidence after a clean-contaminated surgery in Yasuj Shahid Beheshti hospital, Iran. Investigación y Educación en Enfermería 29:3.
Crossref
Crossref
Paul R. Rhomberg & Ronald N. Jones. (2009) Summary trends for the Meropenem Yearly Susceptibility Test Information Collection Program: a 10-year experience in the United States (1999–2008). Diagnostic Microbiology and Infectious Disease 65:4, pages 414-426.
Crossref
Crossref
Katherine M Shea, S Christian Cheatham, David W Smith, Matthew F Wack, Kevin M Sowinski & Michael B Kays. (2009) Comparative Pharmacodynamics of Intermittent and Prolonged Infusions of Piperacillin/Tazobactam Using Monte Carlo Simulations and Steady-State Pharmacokinetic Data from Hospitalized Patients. Annals of Pharmacotherapy 43:11, pages 1747-1754.
Crossref
Crossref
Katherine M. Shea, S. Christian Cheatham, Matthew F. Wack, David W. Smith, Kevin M. Sowinski & Michael B. Kays. (2009) Steady-state pharmacokinetics and pharmacodynamics of piperacillin/tazobactam administered by prolonged infusion in hospitalised patients. International Journal of Antimicrobial Agents 34:5, pages 429-433.
Crossref
Crossref
Helen Giamarellou & Garyphallia Poulakou. (2009) Multidrug-Resistant Gram-Negative Infections. Drugs 69:14, pages 1879-1901.
Crossref
Crossref
Jason A. Roberts, Carl M. J. Kirkpatrick, Michael S. Roberts, Thomas A. Robertson, Andrew J. Dalley & Jeffrey Lipman. (2009) Meropenem dosing in critically ill patients with sepsis and without renal dysfunction: intermittent bolus versus continuous administration? Monte Carlo dosing simulations and subcutaneous tissue distribution. Journal of Antimicrobial Chemotherapy 64:1, pages 142-150.
Crossref
Crossref
Jared L Crandon, Joseph L Kuti, Ronald N Jones & David P Nicolau. (2009) Comparison of 2002–2006 OPTAMA Programs for US Hospitals: Focus on Gram-Negative Resistance. Annals of Pharmacotherapy 43:2, pages 220-227.
Crossref
Crossref
K. Vasilev, G. Reshedko, R. Orasan, M. Sanchez, J. Teras, T. Babinchak, G. Dukart, A. Cooper, N. Dartois, H. Gandjini, R. Orrico & E. Ellis-Grosse. (2008) A Phase 3, open-label, non-comparative study of tigecycline in the treatment of patients with selected serious infections due to resistant Gram-negative organisms including Enterobacter species, Acinetobacter baumannii and Klebsiella pneumoniae. Journal of Antimicrobial Chemotherapy 62:Supplement 1, pages i29-i40.
Crossref
Crossref
S. Christian Cheatham, Michael B. Kays, David W. Smith, Matthew F. Wack & Kevin M. Sowinski. (2012) Steady‐State Pharmacokinetics and Pharmacodynamics of Meropenem in Hospitalized Patients. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy 28:6, pages 691-698.
Crossref
Crossref
Ronald N. Jones, Jeffrey T. Kirby & Paul R. Rhomberg. (2008) Comparative activity of meropenem in US medical centers (2007): initiating the 2nd decade of MYSTIC program surveillance. Diagnostic Microbiology and Infectious Disease 61:2, pages 203-213.
Crossref
Crossref
Azar Hadadi, Mehrnaz Rasoulinejad, Zohreh Maleki, Masoud Yonesian, Afsaneh Shirani & Zahra Kourorian. (2008) Antimicrobial resistance pattern of Gram-negative bacilli of nosocomial origin at 2 university hospitals in Iran. Diagnostic Microbiology and Infectious Disease 60:3, pages 301-305.
Crossref
Crossref
Paul R. Rhomberg, Lalitagauri M. Deshpande, Jeffrey T. Kirby & Ronald N. Jones. (2007) Activity of meropenem as serine carbapenemases evolve in US Medical Centers: monitoring report from the MYSTIC Program (2006). Diagnostic Microbiology and Infectious Disease 59:4, pages 425-432.
Crossref
Crossref
C. Andrew DeRyke, Joseph L. Kuti & David P. Nicolau. (2007) Reevaluation of current susceptibility breakpoints for Gram-negative rods based on pharmacodynamic assessment. Diagnostic Microbiology and Infectious Disease 58:3, pages 337-344.
Crossref
Crossref
C. Andrew DeRyke, Mary Anne Banevicius, Hong Wei Fan & David P. Nicolau. (2007)
Bactericidal Activities of Meropenem and Ertapenem against Extended-Spectrum-β-Lactamase-Producing
Escherichia coli
and
Klebsiella pneumoniae
in a Neutropenic Mouse Thigh Model
. Antimicrobial Agents and Chemotherapy 51:4, pages 1481-1486.
Crossref
Crossref
C. Andrew DeRyke, Joseph L. Kuti & David P. Nicolau. (2012)
Pharmacodynamic Target Attainment of Six β‐Lactams and Two Fluoroquinolones Against
Pseudomonas aeruginosa, Acinetobacter baumannii, Escherichia coli
, and
Klebsiella
Species Collected from United States Intensive Care Units in 2004
. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy 27:3, pages 333-342.
Crossref
Crossref
C. Andrew DeRyke & David P. Nicolau. (2007) Is all free time above the minimum inhibitory concentration the same: implications for β-lactam in vivo modelling. International Journal of Antimicrobial Agents 29:3, pages 341-343.
Crossref
Crossref
Paul R. Rhomberg & Ronald N. Jones. (2007) Contemporary activity of meropenem and comparator broad-spectrum agents: MYSTIC program report from the United States component (2005). Diagnostic Microbiology and Infectious Disease 57:2, pages 207-215.
Crossref
Crossref
Charles Andrew DeRyke, Joseph L. Kuti & David P. Nicolau. (2007) Changes in Pharmacodynamic Target Attainment for Antimicrobials Over a 2-Year Period. Infectious Diseases in Clinical Practice 15:1, pages 26-34.
Crossref
Crossref
Ken B. Waites, Lynn B. Duffy & Michael J. Dowzicky. (2006) Antimicrobial Susceptibility among Pathogens Collected from Hospitalized Patients in the United States and In Vitro Activity of Tigecycline, a New Glycylcycline Antimicrobial. Antimicrobial Agents and Chemotherapy 50:10, pages 3479-3484.
Crossref
Crossref